Skip to Main Content

The press release issued by pharmaceutical companies Eisai and Biogen on Sept. 27 might someday be remembered as the beginning of a revolution in Alzheimer’s diagnosis and treatment.

Years and years of failed Alzheimer’s trials created, and then fortified, doubts about whether drugs that attacked amyloid, a brain protein linked to Alzheimer’s disease, were a valid approach to its treatment. Those doubts may have been quelled.

advertisement

The companies reported so-called top-line results of CLARITY-AD, a study of their drug lecanemab, among individuals with either mild cognitive impairment (MCI) or mild-stage dementia and evidence of accumulation of amyloid in their brain. “Top line” describes overall summaries of the results of the primary and secondary endpoints.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe

STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect

To submit a correction request, please visit our Contact Us page.